Literature DB >> 1469463

The taiep rat: a myelin mutant with an associated oligodendrocyte microtubular defect.

I D Duncan1, K F Lunn, B Holmgren, R Urba-Holmgren, L Brignolo-Holmes.   

Abstract

This report describes a new inherited disorder of myelination in the rat, named taiep, in which failure of normal myelination of the CNS and subsequent demyelination result in a progressive neurological disturbance. At two months of age, myelin is present throughout the spinal cord, but is immature in the fasciculus gracilis and corticospinal tracts despite the presence of abundant oligodendrocytes. By 12 months, myelin has largely been lost in these spinal cord tracts and also in more rostral parts of the CNS, such as the cerebellum and optic nerves. Other funiculi of the spinal cord show a more diffuse lack of myelin. Oligodendrocytes develop a unique cellular abnormality, most obviously in older rats, which is characterized by the accumulation of microtubules throughout their cytoplasm. As the mutant rats age, there is a continued protracted breakdown of myelin throughout the CNS, with evidence suggesting either persistent hypomyelination or attempts at remyelination of affected axons. It is proposed that the microtubular defect in oligodendrocytes results in a disruption of the normal myelination process in certain areas of the CNS of this mutant, and eventually leads to failure of maintenance of the myelin sheath.

Entities:  

Mesh:

Year:  1992        PMID: 1469463     DOI: 10.1007/bf01191684

Source DB:  PubMed          Journal:  J Neurocytol        ISSN: 0300-4864


  20 in total

1.  In utero PCP exposure alters oligodendrocyte differentiation and myelination in developing rat frontal cortex.

Authors:  Josette S Lindahl; Barton R Kjellsen; Jamie Tigert; Robin Miskimins
Journal:  Brain Res       Date:  2008-07-15       Impact factor: 3.252

Review 2.  Schwann cell invasion of the central nervous system of the myelin mutants.

Authors:  I D Duncan; R L Hoffman
Journal:  J Anat       Date:  1997-01       Impact factor: 2.610

Review 3.  Transplanting oligodendrocyte progenitors into the adult CNS.

Authors:  R J Franklin; W F Blakemore
Journal:  J Anat       Date:  1997-01       Impact factor: 2.610

4.  General control nonderepressible 2 (GCN2) kinase protects oligodendrocytes and white matter during branched-chain amino acid deficiency in mice.

Authors:  Pengxiang She; Piyawan Bunpo; Judy K Cundiff; Ronald C Wek; Robert A Harris; Tracy G Anthony
Journal:  J Biol Chem       Date:  2013-09-09       Impact factor: 5.157

5.  Insertion of a retrotransposon in Mbp disrupts mRNA splicing and myelination in a new mutant rat.

Authors:  L T O'Connor; B D Goetz; J M Kwiecien; K H Delaney; A L Fletch; I D Duncan
Journal:  J Neurosci       Date:  1999-05-01       Impact factor: 6.167

Review 6.  Glial grafting for demyelinating disease.

Authors:  V Tepavcević; W F Blakemore
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-09-29       Impact factor: 6.237

Review 7.  The myelin mutants as models to study myelin repair in the leukodystrophies.

Authors:  Ian D Duncan; Yoichi Kondo; Su-Chun Zhang
Journal:  Neurotherapeutics       Date:  2011-10       Impact factor: 7.620

8.  A mutation in the Tubb4a gene leads to microtubule accumulation with hypomyelination and demyelination.

Authors:  Ian D Duncan; Marianna Bugiani; Abigail B Radcliff; John J Moran; Camila Lopez-Anido; Phu Duong; Benjamin K August; Nicole I Wolf; Marjo S van der Knaap; John Svaren
Journal:  Ann Neurol       Date:  2017-05-09       Impact factor: 10.422

9.  Altered synaptic and electrical properties of lumbar motoneurons in the neurological glial mutant taiep rat.

Authors:  Christian Bonansco; Marco Fuenzalida; Manuel Roncagliolo
Journal:  Exp Brain Res       Date:  2003-12-19       Impact factor: 1.972

10.  Myelin loss does not lead to axonal degeneration in a long-lived model of chronic demyelination.

Authors:  Chelsey M Smith; Elizabeth Cooksey; Ian D Duncan
Journal:  J Neurosci       Date:  2013-02-06       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.